Actinium Pharmaceuticals, Inc. (ATNM)
ATNM Stock Price Chart
Explore Actinium Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ATNM price movements and trends.
ATNM Company Profile
Discover essential business fundamentals and corporate details for Actinium Pharmaceuticals, Inc. (ATNM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Dec 2012
Employees
31.00
Website
https://www.actiniumpharma.comCEO
Sandesh C. Seth
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
ATNM Financial Timeline
Browse a chronological timeline of Actinium Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.25.
Earnings released on 8 Aug 2025
EPS came in at -$0.22 surpassing the estimated -$0.32 by +31.25%.
Earnings released on 9 May 2025
EPS came in at -$0.51 falling short of the estimated -$0.26 by -96.15%.
Earnings released on 31 Mar 2025
EPS came in at -$0.21 surpassing the estimated -$0.37 by +43.24%, while revenue for the quarter reached $810.00K .
Earnings released on 14 Nov 2024
EPS came in at -$0.37 falling short of the estimated -$0.35 by -5.71%.
Earnings released on 5 Aug 2024
EPS came in at -$0.38 surpassing the estimated -$0.48 by +20.83%.
Earnings released on 26 Apr 2024
EPS came in at -$0.31 surpassing the estimated -$0.42 by +26.19%.
Earnings released on 29 Mar 2024
EPS came in at -$0.33 surpassing the estimated -$0.54 by +38.89%, while revenue for the quarter reached $81.00K .
Earnings released on 2 Nov 2023
EPS came in at -$0.49 surpassing the estimated -$0.53 by +7.55%.
Earnings released on 14 Aug 2023
EPS came in at -$0.58 falling short of the estimated -$0.50 by -16.00%.
Earnings released on 15 May 2023
EPS came in at -$0.43 falling short of the estimated -$0.42 by -2.38%.
Earnings released on 3 Apr 2023
EPS came in at -$0.42 falling short of the estimated -$0.26 by -61.54%, while revenue for the quarter reached $114.00K .
Earnings released on 14 Nov 2022
EPS came in at -$0.38 falling short of the estimated -$0.30 by -26.67%, while revenue for the quarter reached $45.00K , missing expectations by -92.24%.
Earnings released on 12 Aug 2022
EPS came in at -$0.33 falling short of the estimated -$0.23 by -43.48%, while revenue for the quarter reached $45.00K , missing expectations by -99.63%.
Earnings released on 13 May 2022
EPS came in at -$0.23 surpassing the estimated -$0.31 by +25.81%, while revenue for the quarter reached $940.00K , beating expectations by +1.44%.
Earnings released on 25 Mar 2022
EPS came in at -$0.36 falling short of the estimated -$0.30 by -20.00%, while revenue for the quarter reached $23.00K , missing expectations by -78.44%.
Earnings released on 12 Nov 2021
EPS came in at -$0.30 falling short of the estimated -$0.29 by -3.45%, while revenue for the quarter reached $233.00K , beating expectations by +3.57%.
Earnings released on 30 Jul 2021
EPS came in at -$0.25 surpassing the estimated -$0.30 by +16.67%, while revenue for the quarter reached $266.00K , meeting expectations.
Earnings released on 14 May 2021
EPS came in at -$0.29 matching the estimated -$0.29, while revenue for the quarter reached $622.00K , meeting expectations.
Earnings released on 31 Mar 2021
EPS came in at -$0.37 matching the estimated -$0.37.
Earnings released on 23 Oct 2020
EPS came in at -$0.36 surpassing the estimated -$0.44 by +18.18%.
ATNM Stock Performance
Access detailed ATNM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.